This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Sep 18;146(12):1379-1380.

doi: 10.1182/blood.2025029797.

Immunochemotherapy for older patients with ATLL: a new option?

Ambroise Marçais¹

Affiliations

PMID: 40965942
DOI: 10.1182/blood.2025029797

Editorial

Immunochemotherapy for older patients with ATLL: a new option?

Ambroise Marçais. Blood. 2025.

. 2025 Sep 18;146(12):1379-1380.

doi: 10.1182/blood.2025029797.

Author

Ambroise Marçais¹

Affiliation

¹ Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants Malades.

PMID: 40965942
DOI: 10.1182/blood.2025029797

No abstract available

PubMed Disclaimer

Comment on

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.
Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K. Yoshimitsu M, et al. Blood. 2025 Sep 18;146(12):1440-1449. doi: 10.1182/blood.2024027902. Blood. 2025. PMID: 40373281 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems